Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan plus Bevacizumab in TNBC with Brain Metastases
NCT07623577Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC), brain metastasis (BM), sponsored by Fudan University. Started Jan 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)brain metastasis (BM)
Beyond the preview
Go deeper on NCT07623577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623577.